No Data
Net income sharply declined with the contraction of overseas sales, Botai Biology opens up the microfluidic testing field | Earnings conference
①The rapid decline in overseas income dragged down the performance of Botuo Life Sciences, with overall revenue significantly decreasing compared to before the epidemic, and net income attributable to shareholders has decreased year-on-year for multiple years; ② Considering changes in the external environment, Botuo Life Sciences has terminated two major core investment projects, added the Microfluidic Fluorescence Detection Platform project, and ventured into the microfluidic technology field.
Botuo Biotech Report for the Third Quarter of 2024
Botao Biology (688767.SH): Plans to launch an employee stock ownership plan in 2024.
Galaxy Comprehensive News September 25th | Botuo Biotechnology (688767.SH) announced the 2024 employee stock ownership plan, the stocks in this employee stock ownership plan come from the company's repurchase special account to repurchase Botuo Biotechnology A ordinary shares. The target stocks to be held in this employee stock ownership plan will not exceed 2.15 million shares, accounting for approximately 2.02% of the total 106.666667 million shares of the company's capital stock on the date the draft of this employee stock ownership plan was announced. The funds for this employee stock ownership plan come from legitimate employee compensation, self-raised funds, and other methods allowed by laws and regulations. The company does not provide financial assistance or loans to shareholders.
Hangzhou Biotest BiotechLtd's (SHSE:688767) Shareholders May Want To Dig Deeper Than Statutory Profit
Summary of Botuo Biotech\'s 2024 Semi-Annual Report
Botuo Biotech 2024 Semi-Annual Report
